Testing combination therapy before surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests if adding immunotherapy and an anti-angiogenesis drug to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer that has not spread. You may benefit if your tumor is in the lower part of the rectum and you haven't had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years old
- Diagnosed with rectal cancer that has not spread to other organs
- Tumor is considered surgically removable
- Have not received any prior treatment for rectal cancer
- Able to swallow pills and are in generally good health (ECOG 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
This study tests whether combining mFOLFOX6 chemotherapy with an immunotherapy drug (anti-PD-1) before surgery can shrink locally advanced rectal cancer. It is open to people whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
This trial tests giving chemotherapy (mFOLFOXIRI) plus bevacizumab before surgery for rectal cancer that has higher-risk features. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.